AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32276179
Drug: Paclitaxel (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (90 mg/m2 on days 1, 8, 15) plus Bevacizumab (10 mg/kg on days 1, 15) every 28 days
Trial: 32276179
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2) every 21 days
Trial: 35093535
Drug: Intravenous triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous triiodothyronine (T3) supplementation
Trial: 32325038
Drug: ChAdOx1 MERS
RxNorm normalized name: mersalyl
DrugBank: Mersalyl (DB09338)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 MERS (all doses)
Trial: 32325038
Drug: ChAdOx1 MERS
RxNorm normalized name: mersalyl
DrugBank: Mersalyl (DB09338)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 MERS (high-dose)
Trial: 33270026
Drug: WeChat intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WeChat intervention providing breastfeeding knowledge and promotion information weekly from third month of pregnancy to 6 months postpartum
Trial: 34543474
Drug: Proactive management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive management with Cal/BD foam (twice weekly)
Trial: 34543474
Drug: Reactive management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reactive management with vehicle foam (twice weekly)
Trial: 34543474
Drug: Cal/BD foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cal/BD foam (once daily) during initial 4-week phase
Trial: 34023810
Drug: Fenfluramine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine (0.2 mg/kg/day, titrated to maximum 26 mg/day)
Trial: 34426012
Drug: Sodium-glucose cotransporter
RxNorm normalized name: glucose / sodium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium-glucose cotransporter 2 inhibitors (SGLT2is)
Trial: 35590054
Drug: Intravitreal ziv-aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ziv-aflibercept (IVZ) 1.25 mg/0.05 ml
Trial: 33449919
Drug: Exendin(9-39)NH2 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exendin(9-39)NH2 infusion during acarbose treatment
Trial: 33449919
Drug: Exendin(9-39)NH2 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exendin(9-39)NH2 infusion during placebo treatment
Trial: 32320843
Drug: Brief advice
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief advice combined with 1-week sample of nicotine replacement therapy (NRT) and active referral to smoking cessation services
Trial: 32281219
Drug: Steroid administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steroid administration in perinatal centers
Trial: 35856361
Drug: L-carnitine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (15 g/bag, orally, twice a day)
Trial: 35856361
Drug: CoQ10 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 (10 mg tablet orally, thrice daily) with Vitamin E (100 mg tablet orally, thrice daily)
Trial: 33032778
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for atorvastatin
Trial: 32961034
Drug: Macimorelin 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macimorelin 2.0 mg/kg
Trial: 32358608
Drug: Online Acceptance
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online Acceptance and Commitment Therapy
Trial: 34359042
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of 1.0 g/kg of 20% mannitol (immediately after anesthesia induction)
Trial: 34359042
Drug: Routine administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine administration of 1.0 g/kg of 20% mannitol (at the time of skin incision)
Trial: 34359042
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of 1.0 g/kg of 20% mannitol
Trial: 34359042
Drug: Routine administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine administration of 1.0 g/kg of 20% mannitol
Trial: 34548383
Drug: Burosumab 1
RxNorm normalized name: Burosumab 10 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Burosumab 1 mg/kg every 4 weeks for 24 weeks
Trial: 34548383
Drug: Burosumab 1
RxNorm normalized name: Burosumab 10 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Burosumab 1 mg/kg every 4 weeks until week 96
Trial: 32622071
Drug: 600 IU
RxNorm normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 IU daily cholecalciferol
Trial: 32622071
Drug: 3750 IU
RxNorm normalized name: Ascorbic Acid/Beta Carotene/Catalase/Cysteine/Glutathione/L-Taurine/Manganese/Orgotein/Selenium/Vitamin A/Vitamin E/Zinc 250 MG-3750 IU-25 MG-25 MG-6.25 MG-50 MG-2 MG-50 MG-0.05 MG-1250 IU-100 IU-7.5 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3750 IU daily cholecalciferol
Trial: 33647273
Drug: Daily acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily acute intermittent hypoxia combined with walking practice (AIH + WALK)
Trial: 36201607
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine oral rinse
Trial: 36201607
Drug: Saline oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline oral rinse
Trial: 35800017
Drug: Neurocognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurocognitive Remediation Therapy (NCRT)
Trial: 34772324
Drug: Sugar (glucose)
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar (glucose) solution
Trial: 34772324
Drug: Non-nutritive sweetener
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-nutritive sweetener (aspartame) solution
Trial: 34029328
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure (PE) therapy, provided within 72 hours after a traumatic event, consisting of three sessions.
Trial: 35475921
Drug: External pneumatic
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External pneumatic compression (EPC) treatment (110 mmHg)
Trial: 35475921
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment control (CTL)
Trial: 33246873
Drug: Individualized self‐management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized self‐management combined with physical therapy
Trial: 32046753
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (rESWT) applied once within 48 hours of menstruation at six abdominal myofascial trigger points.
Trial: 34348351
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IVAI) treat-and-extend (T&E)
Trial: 34348351
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IVAI) T&E plus sham photodynamic therapy (PDT)
Trial: 34348351
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IVAI) T&E plus standard fluence PDT with verteporfin
Trial: 34348351
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IVAI) T&E
Trial: 34348351
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IVAI) T&E plus sham PDT
Trial: 33633278
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 × 150 mg caffeine daily)
Trial: 33633278
Drug: Withdrawal (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal (3 × 150 mg caffeine for 8 days, then switch to placebo)
Trial: 33633278
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 × placebo daily)
Trial: 34171493
Drug: Parent training
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent training intervention (12 therapy sessions)
Trial: 33624806
Drug: Elinzanetant 120
RxNorm normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elinzanetant 120 mg
Trial: 33742316
Drug: Single intravesical
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravesical trigonal-only injection of OnabotulinumtoxinA
Trial: 33742316
Drug: 20 trigone-sparing
RxNorm normalized name: TRIGONELLA FOENUM-GRAECUM WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 trigone-sparing injections of OnabotulinumtoxinA
Trial: 33710268
Drug: Real-world evidence
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real-world evidence studies on diabetes treatments
Trial: 36122605
Drug: Nystatin oral
RxNorm normalized name: nystatin Oral Tablet
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nystatin oral suspension (Control‐100,000IU/mL; 4 × /day)
Trial: 33378447
Drug: 0.8% metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8% metronidazole gel
Trial: 33378447
Drug: SMS reminder
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS reminder and placebo gel
Trial: 34762534
Drug: Laser-Assisted Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser-Assisted Drug Delivery (LADD) with 10% tranexamic acid solution
Trial: 32818951
Drug: Potentially inappropriate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially inappropriate prescriptions
Trial: 34921090
Drug: Cardiovascular preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiovascular preventive medication
Trial: 32178668
Drug: Ropivacaine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine alone (1 mg/kg)
Trial: 32178668
Drug: Ropivacaine combined
RxNorm normalized name: bupivacaine, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine combined with meloxicam (0.2 mg/kg)
Trial: 33128351
Drug: Disease modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease modifying therapy
Trial: 33128351
Drug: Observational studies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observational studies on effectiveness of disease modifying treatments
Trial: 36343847
Drug: Linerixibat 180
RxNorm normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linerixibat 180 mg once daily
Trial: 36343847
Drug: Linerixibat 40
RxNorm normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linerixibat 40 mg twice daily
Trial: 36343847
Drug: Linerixibat 90
RxNorm normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linerixibat 90 mg twice daily
Trial: 36852705
Drug: Linerixibat (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linerixibat (various doses)
Trial: 32618134
Drug: Melatonin 10
RxNorm normalized name: melatonin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 10 mg tablets for 24 weeks
Trial: 36266431
Drug: Silymarin 140
RxNorm normalized name: silymarin 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin 140 mg administered twice daily for 12 weeks
Trial: 39388898
Drug: Pegvaliase treatment
RxNorm normalized name: pegvaliase
DrugBank: Pegvaliase (DB12839)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegvaliase treatment
Trial: 33121884
Drug: Plain bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain bupivacaine (10.9 mg of intrathecal 0.5% plain bupivacaine with 0.2 mg morphine)
Trial: 33121884
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine (10.9 mg of intrathecal 0.5% hyperbaric bupivacaine with 0.2 mg morphine)
Trial: 32993573
Drug: Vagus Nerve
RxNorm normalized name: SUS SCROFA VAGUS NERVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagus Nerve Stimulation (VNS) Therapy
Trial: 33799302
Drug: Stent retrievers
RxNorm normalized name: castor fiber scent gland secretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stent retrievers as primary treatment device
Trial: 32236953
Drug: Licogliflozin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licogliflozin (50 mg q.d.) with a 50% carbohydrate meal
Trial: 32236953
Drug: Licogliflozin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licogliflozin (50 mg q.d.) with a 0% carbohydrate meal
Trial: 32236953
Drug: Psyllium 6
RxNorm normalized name: psyllium 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium 6 g or calcium carbonate 1 g supplementation
Trial: 34560319
Drug: Twice-daily iTBS
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily iTBS (600 pulses)
Trial: 34560319
Drug: Once-daily iTBS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily iTBS (1200 pulses)
Trial: 35153479
Drug: Combination low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combination low-dose theophylline (100mg bd) and prednisone (5mg qd)
Trial: 32910531
Drug: Tofacitinib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (both doses)
Trial: 33141883
Drug: Osteomyelitis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteomyelitis treatment
Trial: 35712800
Drug: Bromocriptine quick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine quick release (BCQR) titrated from 0.8 mg to 1.6 mg to 3.2 mg (minimum dose 1.6 mg) for 4 weeks
Trial: 33978167
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Fe with 0 mg folic acid
Trial: 33978167
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Fe with 0.4 mg folic acid
Trial: 33978167
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Fe with 2.8 mg folic acid
Trial: 35652772
Drug: ACB‐IPACK block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACB‐IPACK block (30 mL bupivacaine 0.25%)
Trial: 35652772
Drug: Adductor canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adductor canal block (ACB) (20 mL bupivacaine 0.25%)
Trial: 36331326
Drug: Inclisiran (284
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclisiran (284 mg administered on Days 1, 90, and every 6 months thereafter for 18 months)
Trial: 34126308
Drug: Behavioral Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Activation Therapy for Anhedonia (BATA)
Trial: 34256199
Drug: Dual transcranial
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual transcranial direct current stimulation (dual tDCS) and modified constraint-induced movement therapy (mCIMT)
Trial: 34256199
Drug: Sham dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham dual tDCS and modified constraint-induced movement therapy (mCIMT)
Trial: 36104267
Drug: Sodium benzoate
RxNorm normalized name: Sodium Benzoate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium benzoate 250 mg
Trial: 36104267
Drug: Sodium benzoate
RxNorm normalized name: Sodium Benzoate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium benzoate 500 mg
Trial: 36104267
Drug: Sodium benzoate
RxNorm normalized name: Sodium Benzoate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium benzoate 1000 mg
Trial: 36104267
Drug: Sodium benzoate
RxNorm normalized name: Sodium Benzoate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium benzoate 2000 mg
Trial: 36104267
Drug: Sodium benzoate
RxNorm normalized name: Sodium Benzoate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium benzoate (all doses)
Trial: 33382916
Drug: LY2775240 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2775240 (20 mg)
Trial: 33382916
Drug: Apremilast (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast (30 mg)
Trial: 36013087
Drug: Nefopam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (20 mg after induction and 15 min before the end of surgery)
Trial: 33813948
Drug: Both options
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both options (intensive lifestyle change and metformin)
Trial: 34408675
Drug: Individual cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive behavioral therapy (iCBT) plus treatment-as-usual (TAU)
Trial: 37146874
Drug: Treatment-as-usual (TAU)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (TAU) only
Trial: 33372439
Drug: Interferential current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferential current therapy (IFC), active therapy, three times per week for four weeks
Trial: 34791009
Drug: Plant sterols
RxNorm normalized name: Plant Sterols/Stanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterols (PSs) 2 g/d for 28 days
Trial: 34567960
Drug: 4-weekly BTA
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4-weekly BTA treatment
Trial: 34567960
Drug: 12-weekly BTA
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-weekly BTA treatment
Trial: 35688164
Drug: tixagevimab–cilgavimab 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tixagevimab–cilgavimab 600 mg (two consecutive 3 mL intramuscular injections, 300 mg tixagevimab and 300 mg cilgavimab)
Trial: 35688164
Drug: tixagevimab–cilgavimab 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tixagevimab–cilgavimab 600 mg
Trial: 33271319
Drug: Micronized vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized vaginal progesterone (MVP) gel
Trial: 36055978
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral ondansetron (0.33 mg twice daily)
Trial: 36036121
Drug: Prednisone 2
RxNorm normalized name: prednisone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 2 mg/(kg·day) (maximum 60 mg) for 4 weeks
Trial: 36036121
Drug: Prednisone 2
RxNorm normalized name: prednisone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 2 mg/(kg·day) (maximum 60 mg) for 6 weeks
Trial: 36036121
Drug: Prednisone treatment
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone treatment for 4 weeks
Trial: 36036121
Drug: Prednisone treatment
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone treatment for 6 weeks
Trial: 36004653
Drug: Tirzepatide (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (5, 10, and 15 mg)
Trial: 32291277
Drug: Tirzepatide (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (10, 15 mg)
Trial: 35143800
Drug: Methotrexate 25
RxNorm normalized name: methotrexate 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 25 mg weekly
Trial: 35143800
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil 1.5 g twice daily
Trial: 35143800
Drug: Methotrexate 25
RxNorm normalized name: methotrexate 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 25 mg weekly (for those who switched treatment)
Trial: 35143800
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil 1.5 g twice daily (for those who switched treatment)
Trial: 32617631
Drug: Oral opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral opioid rescue medication (hydromorphone) in Cohort 1 (C1)
Trial: 32617631
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia (PCIA) with piritramide in Cohort 2 (C2)
Trial: 35551086
Drug: Irreversible electroporation
RxNorm normalized name: Adult allogeneic CD4+ and CD8+ enriched T cells transduced with an anti-CD19 chimeric antigen receptor (CAR) that is site-specific integrated into the cellular genome. Adult allogeneic CD4+ and CD8+ enriched T cells, gene edited through the electroporati
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irreversible electroporation (IRE) followed by further chemotherapy if indicated
Trial: 35551086
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (standard of care)
Trial: 33774192
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution with conventional cementation system (etch‐and‐rinse adhesive)